← Leaderboards
Ronald B Moss
Vical, Inc.
$1,047,535
Attributed
$1,047,535
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,047,535 · 1
By mechanism
R44$1,047,535 · 1
Top collaborators
No co-investigators on record.
Most similar at Vical, Inc.
Same institution · by research overlap
- Lawrence R Smith$9,015,929
- David C. Kaslow$2,089,603
- Mary K Wloch$258,937
- Sean M. Sullivan$1,999,533
Others in their field
Top investigators on “Antiviral Agents”
- Constance Ann Benson · University Of California, San Diego$209,152,068
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$120,325,769
- Judith S. Currier · University Of California Los Angeles$102,391,456
- Beth Baseler · Leidos Biomedical Research, Inc.$83,440,795
- Sharon A Nachman · Johns Hopkins University$77,262,665
- John Damon Chodera · Sloan-Kettering Inst Can Research$58,660,403
Research focus
Antiviral AgentsCellsChinaClinical TrialsClinical Trials, Phase IClinical Trials, Phase IiCytomegalovirusCytomegalovirus VaccinesEfficacy TrialEnd PointEvaluationFundingGenerationsGenesGuanosine MonophosphateHematopoieticImmunogenicityImmunotherapeutic AgentLicensureMalariaManufacturer NameOrgan TransplantationPlasmid DnaPlasmids